AngioDynamics Announces First Patient Enrollment in RAPID Outcomes Database
Thursday, August 6, 2015
AngioDynamics (Nasdaq:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, today announce the enrollment of the first patient into the Registry of AngioVac Procedures In Detail (RAPID) Database at University of California-Los Angeles (UCLA) Health in Los Angeles, California.
The RAPID Database is designed to evaluate the patterns of use as well as safety and effectiveness data of the AngioVac® system in the en bloc removal of fresh, soft thrombi or emboli.
According to national principal investigator, Dr. John M. Moriarty, Assistant Professor of Radiology, Director of Cardiology-Interventional Radiology Innovation at UCLA, there has been significant interest in centers wanting to participate in the Registry.
"So far, we have centers in 31 states that want to take part in the Registry," said Dr. Moriarty. "Our goal is to include as many potential collaborators as possible, and start gathering much needed data regarding procedural and patient outcomes."
Dr. Moriarty added that the registry is also a way to become part of the community of physicians, nurses, and technologists who are working in this field, and connecting with researchers who may not be anywhere near you geographically, but by working with RAPID, "you can become part of a wider group of experts."
"AngioVac continues to impress clinically as the second-generation of the device, cleared for use earlier this year by the U.S. Food and Drug Administration (FDA) and released to the market in April, is driving broader interest among clinicians," said Chris Crisman, AngioDynamics' Senior Vice President, Global Franchise Leader. "AngioDynamics is a pioneer when it comes to the minimally invasive en bloc removal of fresh, soft thrombi or emboli. We feel we have a responsibility to work with our physician partners to gather patient data and continue improving our procedures, products and patient outcomes. We are excited to launch this initiative and look forward to the collaboration which in the end will benefit patients."
The primary objective of RAPID is to capture high quality patient safety and effectiveness data on use of the AngioVac system for various anatomic locations. The goal will be achieved by capturing a concise set of immediate and short-term functional and clinical outcome data for all patients who have the AngioVac catheter deployed into their venous system. Secondarily, registry objectives will be to study, assess, and benchmark clinical practice patterns. These objectives will be achieved through the capture of selected process data for patients included in the registry. Data collected in this study may also be used to develop and refine standards of care for use of AngioVac and to facilitate the design of randomized clinical trials.
RAPID is funded by a registry agreement provided by AngioDynamics.
AngioDynamics Inc. is a leading provider of innovative, minimally invasive medical devices used by professional healthcare providers for vascular access, surgery, peripheral vascular disease and oncology. AngioDynamics' diverse product lines include market-leading ablation systems, fluid management systems, vascular access products, angiographic products and accessories, angioplasty products, drainage products, thrombolytic products and venous products. More information is available at www.AngioDynamics.com.
AngioDynamics, the AngioDynamics logo, and AngioVac are trademarks and/or registered trademarks of AngioDynamics Inc., an affiliate or a subsidiary.
This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements regarding AngioDynamics' expected future financial position, results of operations, cash flows, business strategy, budgets, projected costs, capital expenditures, products, competitive positions, growth opportunities, plans and objectives of management for future operations, as well as statements that include the words such as "expects," "reaffirms," "intends," "anticipates," "plans," "believes," "seeks," "estimates," "optimistic," or variations of such words and similar expressions, are forward-looking statements. These forward looking statements are not guarantees of future performance and are subject to risks and uncertainties. Investors are cautioned that actual events or results may differ from AngioDynamics' expectations. Factors that may affect the actual results achieved by AngioDynamics include, without limitation, the ability of AngioDynamics to develop its existing and new products, technological advances and patents attained by competitors, future actions by the FDA or other regulatory agencies, domestic and foreign health care reforms and government regulations, results of pending or future clinical trials, overall economic conditions, the results of on-going litigation, the effects of economic, credit and capital market conditions, general market conditions, market acceptance, foreign currency exchange rate fluctuations, the effects on pricing from group purchasing organizations and competition, the ability of AngioDynamics to integrate purchased businesses, as well as the risk factors listed from time to time in AngioDynamics' SEC filings, including but not limited to its Annual Report on Form 10-K for the year ended May 31, 2014; its Annual Report on Form 10-K/A for the fiscal year ended May 31, 2014; its quarterly reports on form 10-Q for the fiscal quarters ended August 31, 2014, and November 30, 2014; and the current report on Form 8-K, filed with the SEC on March 2, 2015. AngioDynamics does not assume any obligation to publicly update or revise any forward-looking statements for any reason.